First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

Summary

This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate to evaluate the efficacy and safety of first line atezolizumab in combination with paclitaxel and bevacizumab (Avastin®) in patients with advanced or metastatic triple-negative breast cancer (mTNBC)

Timeline

Start

2020-10-05

Primary completion

2023-12-07

Completion

2023-12-07

Outcome

Met primary endpoint

paper The primary endpoint was met, with a median progression-free survival of 11.0 months (95% confidence interval (CI): 9.0-13.4; P < 0.001). PMID 40467896 ↗

Publications

• Gion M, Blancas I, Cortez-Castedo P, Cortes-Salgado A, Marme F, Blanch S, Morales S, Diaz N, Calvo-Plaza I, Recalde S, Martinez-Bueno A, Ruiz-Borrego M, Llabres E, Taberner MT, de Laurentiis M, Garcia-Vicente S, Guerrero JA, Boix O, Rodriguez-Morato J, Sampayo-Cordero M, Antonarelli G, Perez-Garcia JM, Cortes J, Llombart-Cussac A; ATRACTIB Trial Investigators. Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial. Nat Med. 2025 Aug;31(8):2746-2754. doi: 10.1038/s41591-025-03734-3. Epub 2025 Jun 4.
• Agostinetto E, Eiger D, Punie K, de Azambuja E. Emerging Therapeutics for Patients with Triple-Negative Breast Cancer. Curr Oncol Rep. 2021 Mar 24;23(5):57. doi: 10.1007/s11912-021-01038-6.

Drugs

Indications